PRO 1107
Alternative Names: GEN-1107; PRO-1107Latest Information Update: 16 Oct 2025
At a glance
- Originator ProfoundBio
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 15 Sep 2025 Genmab terminates phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in the USA and China (IV) (NCT06171789)
- 21 May 2024 ProfoundBio has been acquired by Genmab
- 29 Jan 2024 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in China (IV) (NCT06171789)